ARCHIVES

Reports On AACR Scientific Sessions

This article is from The Cancer Letter archive.

Vol. 02 No. 21 | May 21, 1976

Download PDF Visit The Full Archive

Related Articles

Cancer Act Renewals Marked By Disputes Over NCI Authorities

October 5, 1990

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006

Two Studies Demonstrate Molecule Blocking Cell Damage

August 26, 2011

FDA, NCI, Congress Shape Pediatric Drug Development Proposals

April 11, 2003

FCRC Recompetition To Be Split Into Two Major Contract, For Research And “Everything Else”

September 5, 1980

ONS Votes to Push Congress on DRGs

June 1, 1984